BACKGROUND. Over the past decade, a number of new therapeutic agents have become
available in the treatment of metastatic breast cancer (MBC). This study characterized the use …

Background Gene expression profiling of breast cancer has identified two biologically
distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B. …

Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen
receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16…

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Purpose: Basal-like breast cancer is associated with high grade, poor prognosis, and
younger patient age. Clinically, a triple-negative phenotype definition [estrogen receptor, …

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …

Purpose Adjuvant! ( www.adjuvantonline.com ) is a web-based tool that predicts 10-year
breast cancer outcomes with and without adjuvant systemic therapy, but it has not been …

Carbonic anhydrase IX (CAIX) is a hypoxia and HIF-1–inducible protein that regulates intra-
and extracellular pH under hypoxic conditions and promotes tumor cell survival and …

Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…

Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4,
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …